BACKGROUND: Breast cancer is one of the most frequent causes of leptomeningeal metastasis (LM) among solid tumors in adults. The prognosis of patients with LM is poor. A treatment option is the intrathecal administration of liposomal cytarabine. CASE REPORTS: The first case represents a 53-year-old woman with LM of breast cancer. A neurological response was achieved shortly after the start of the multimodal treatment including intrathecal liposomal cytarabine. The response duration reached 79 days. The second case represents a 48-year-old woman with LM of breast cancer treated with intrathecal liposomal cytarabine as a part of a multimodal treatment approach. A neurological response was achieved in the first 2 weeks of treatment and is still lasting after 18 months. CONCLUSION: These cases suggest that a rapid response to a prompt start of treatment with intrathecal liposomal cytarabine in patients with LM of breast cancer is feasible. In 1 case an extremely long progression-free survival (18+ months) was achieved. The cases support the efficacy of liposomal cytarabine in the management of LM in breast cancer patients as a part of a multimodal treatment approach and underline the need for further investigations in this specific cohort.
BACKGROUND:Breast cancer is one of the most frequent causes of leptomeningeal metastasis (LM) among solid tumors in adults. The prognosis of patients with LM is poor. A treatment option is the intrathecal administration of liposomal cytarabine. CASE REPORTS: The first case represents a 53-year-old woman with LM of breast cancer. A neurological response was achieved shortly after the start of the multimodal treatment including intrathecal liposomal cytarabine. The response duration reached 79 days. The second case represents a 48-year-old woman with LM of breast cancer treated with intrathecal liposomal cytarabine as a part of a multimodal treatment approach. A neurological response was achieved in the first 2 weeks of treatment and is still lasting after 18 months. CONCLUSION: These cases suggest that a rapid response to a prompt start of treatment with intrathecal liposomal cytarabine in patients with LM of breast cancer is feasible. In 1 case an extremely long progression-free survival (18+ months) was achieved. The cases support the efficacy of liposomal cytarabine in the management of LM in breast cancerpatients as a part of a multimodal treatment approach and underline the need for further investigations in this specific cohort.
Entities:
Keywords:
Breast cancer; Leptomeningeal metastasis; Liposomal cytarabine
Authors: M J Glantz; K A Jaeckle; M C Chamberlain; S Phuphanich; L Recht; L J Swinnen; B Maria; S LaFollette; G B Schumann; B F Cole; S B Howell Journal: Clin Cancer Res Date: 1999-11 Impact factor: 12.531
Authors: Soohyeon Lee; Hee Kyung Ahn; Yeon Hee Park; Do Hyun Nam; Jung Il Lee; Won Park; Doo Ho Choi; Seung Jae Huh; Kyung Tae Park; Jin Seok Ahn; Young-Hyuck Im Journal: Breast Cancer Res Treat Date: 2011-07-23 Impact factor: 4.872
Authors: Jose A Garcia-Marco; Carlos Panizo; Eva Sanchez Garcia; Guillermo Deben; Alberto Alvarez-Larran; Eva Gonzalez Barca; Juan Manuel Sancho; Maria Jesus Penarrubia; Tomas Garcia-Cerecedo; Jose A Garcia Vela Journal: Cancer Date: 2009-05-01 Impact factor: 6.860
Authors: E Le Rhun; S Taillibert; F Zairi; N Kotecki; P Devos; A Mailliez; V Servent; L Vanlemmens; P Vennin; T Boulanger; M C Baranzelli; C André; G Marliot; J L Cazin; F Dubois; R Assaker; J Bonneterre; M C Chamberlain Journal: J Neurooncol Date: 2013-03-01 Impact factor: 4.130
Authors: F Mack; B G Baumert; N Schäfer; E Hattingen; B Scheffler; U Herrlinger; M Glas Journal: Cancer Treat Rev Date: 2015-12-24 Impact factor: 12.111